ophthalmology

News

Two biotechs target dry eye disease after Novartis' Xiidra p...

The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, aiming to disrupt a market led by Allergan and Novartis.

News

UK patient group warns COVID could limit access to Novartis'...

NICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales - but a patient group warned that access could be limited until the pan

News

Roche targets wet AMD with faricimab and its 16-week regimen

Twin late-stage trials of Roche’s ophthalmology drug faricimab have hit the mark in “wet” age-related macular degeneration trial, as the company’s challenge to rivals from Novartis and Baye

News

Roche set to file ophthalmology drug faricimab in DME

Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody showed comparable results in diabetic macular oedema (DME) but with half the in

News

Novartis signs ophthalmology AI deal with RetinAI

Novartis has signed a multi-year agreement with RetinAI, which will see the companies work together to use artificial intelligence (AI) tools to support ophthalmology and digital health pro

News

Janssen adds Hemera's AMD gene therapy to pipeline

Johnson & Johnson’s pharma unit Janssen has bought rights to an investigational gene therapy for a severe form age-related macular degeneration from specialist biotech Hemera Bioscience

Two biotechs target dry eye disease after Novartis' Xiidra p...

UK patient group warns COVID could limit access to Novartis'...

Roche targets wet AMD with faricimab and its 16-week regimen

Roche set to file ophthalmology drug faricimab in DME

Novartis signs ophthalmology AI deal with RetinAI

Janssen adds Hemera's AMD gene therapy to pipeline

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

ophthalmology

Editor's Picks